HRP20192276T1 - Formulacije s produljenim oslobađanjem za dostavu proteina u oko i postupci njihove pripreme - Google Patents

Formulacije s produljenim oslobađanjem za dostavu proteina u oko i postupci njihove pripreme

Info

Publication number
HRP20192276T1
HRP20192276T1 HRP20192276TT HRP20192276T HRP20192276T1 HR P20192276 T1 HRP20192276 T1 HR P20192276T1 HR P20192276T T HRP20192276T T HR P20192276TT HR P20192276 T HRP20192276 T HR P20192276T HR P20192276 T1 HRP20192276 T1 HR P20192276T1
Authority
HR
Croatia
Prior art keywords
eye
procedures
preparation
extended release
release formulations
Prior art date
Application number
HRP20192276TT
Other languages
English (en)
Croatian (hr)
Inventor
Vernon Wong
Louis Wood
Glenn Huang
Original Assignee
Ramscor, Inc.
Icon Bioscience, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramscor, Inc., Icon Bioscience, Inc. filed Critical Ramscor, Inc.
Publication of HRP20192276T1 publication Critical patent/HRP20192276T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts or implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20192276TT 2011-06-10 2012-06-11 Formulacije s produljenim oslobađanjem za dostavu proteina u oko i postupci njihove pripreme HRP20192276T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161495672P 2011-06-10 2011-06-10
EP12829655.5A EP2717914B1 (en) 2011-06-10 2012-06-11 Sustained release formulations for delivery of proteins to the eye and methods of preparing same
PCT/US2012/041950 WO2013036309A2 (en) 2011-06-10 2012-06-11 Sustained release formulations for delivery of proteins to the eye and methods of preparing same

Publications (1)

Publication Number Publication Date
HRP20192276T1 true HRP20192276T1 (hr) 2020-05-15

Family

ID=47832748

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20192276TT HRP20192276T1 (hr) 2011-06-10 2012-06-11 Formulacije s produljenim oslobađanjem za dostavu proteina u oko i postupci njihove pripreme

Country Status (22)

Country Link
US (1) US9814773B2 (https=)
EP (1) EP2717914B1 (https=)
JP (1) JP6339011B2 (https=)
KR (1) KR20140060274A (https=)
CN (1) CN103945865B (https=)
AU (1) AU2012304909B2 (https=)
BR (1) BR112013031685B1 (https=)
CA (1) CA2838289C (https=)
CY (1) CY1122771T1 (https=)
DK (1) DK2717914T3 (https=)
ES (1) ES2761340T3 (https=)
HR (1) HRP20192276T1 (https=)
HU (1) HUE047737T2 (https=)
IN (1) IN2013MN02384A (https=)
LT (1) LT2717914T (https=)
MX (1) MX359119B (https=)
PL (1) PL2717914T3 (https=)
PT (1) PT2717914T (https=)
RS (1) RS60051B1 (https=)
SI (1) SI2717914T1 (https=)
SM (1) SMT202000021T1 (https=)
WO (1) WO2013036309A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2902951T3 (es) * 2013-05-24 2022-03-30 Icon Bioscience Inc Uso de dexametasona de liberación sostenida en la inflamación después de cirugía de cataratas
PL3139914T3 (pl) * 2014-05-08 2023-11-27 Kiora Pharmaceuticals Gmbh Związki stosowane w leczeniu chorób i schorzeń okulistycznych
TWI731853B (zh) * 2015-03-18 2021-07-01 日商參天製藥股份有限公司 徐放性醫藥組成物及其安定化方法
EP3318280A4 (en) * 2015-07-01 2018-08-22 Santen Pharmaceutical Co., Ltd Depot preparation containing citric acid ester
US10786515B2 (en) * 2015-08-03 2020-09-29 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
CA2998504C (en) 2015-09-21 2023-06-20 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
WO2018172850A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
KR101957599B1 (ko) 2017-10-23 2019-03-13 김상현 훈제 단무지 제조 방법, 이에 의해 제조된 훈제 단무지
JP7394770B2 (ja) 2018-02-09 2023-12-08 アイコン バイオサイエンス,インコーポレイテッド 注射器から少量の用量を装填および送達するためのシステム、キット、および方法
AU2019263302C1 (en) 2018-05-01 2024-10-31 Chibi, Inc. Liquid depot for non-invasive sustained delivery of agents to the eye
CN112423740A (zh) 2018-05-01 2021-02-26 奇比有限公司 用于将药物持续递送至视网膜的滴眼剂制剂和方法
JP2023526512A (ja) * 2020-05-22 2023-06-21 トラスティーズ オブ ボストン ユニバーシティ 線維化疾患を処置するための方法および組成物
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
CA3227324A1 (en) 2021-07-06 2023-01-12 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658432B1 (fr) * 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
WO2002000137A1 (en) * 2000-06-28 2002-01-03 Shukla Atul J Biodegradable vehicles and delivery systems of biologically active substances
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
TWI353854B (en) * 2002-06-25 2011-12-11 Alza Corp Short duration depot formulations
MXPA05013003A (es) * 2003-05-30 2006-03-17 Alza Corp Composiciones de deposito elastomerico implantables, usos de las mismas y metodo para elaboracion.
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
EP2452670A1 (en) * 2004-10-01 2012-05-16 Ramscor, Inc. Conveniently implantable sustained release drug compositions
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
BRPI0516308A2 (pt) * 2004-10-04 2010-06-15 Qlt Usa Inc composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
WO2010105093A2 (en) * 2009-03-12 2010-09-16 Delpor, Inc. Implantable device for long-term delivery of drugs
EP2269663B1 (en) * 2009-07-03 2018-03-07 Armbruster Biotechnology GmbH Bone graft and biocomposite

Also Published As

Publication number Publication date
JP6339011B2 (ja) 2018-06-06
WO2013036309A3 (en) 2013-05-10
US20140140992A1 (en) 2014-05-22
MX2013014461A (es) 2014-05-14
EP2717914A4 (en) 2015-05-13
EP2717914B1 (en) 2019-10-30
AU2012304909B2 (en) 2017-06-08
BR112013031685A2 (pt) 2017-02-07
PT2717914T (pt) 2019-12-18
KR20140060274A (ko) 2014-05-19
WO2013036309A2 (en) 2013-03-14
SMT202000021T1 (it) 2020-03-13
DK2717914T3 (da) 2020-01-20
CN103945865B (zh) 2016-10-26
SI2717914T1 (sl) 2020-07-31
CY1122771T1 (el) 2021-05-05
PL2717914T3 (pl) 2020-05-18
MX359119B (es) 2018-09-14
AU2012304909A1 (en) 2013-12-19
IN2013MN02384A (https=) 2015-06-12
JP2014516087A (ja) 2014-07-07
EP2717914A2 (en) 2014-04-16
BR112013031685B1 (pt) 2021-04-06
LT2717914T (lt) 2020-03-25
CA2838289A1 (en) 2013-03-14
NZ619707A (en) 2015-01-30
ES2761340T3 (es) 2020-05-19
HUE047737T2 (hu) 2020-05-28
RS60051B1 (sr) 2020-04-30
CN103945865A (zh) 2014-07-23
CA2838289C (en) 2019-09-10
US9814773B2 (en) 2017-11-14

Similar Documents

Publication Publication Date Title
HRP20192276T1 (hr) Formulacije s produljenim oslobađanjem za dostavu proteina u oko i postupci njihove pripreme
IL286784A (en) Compositions of protein and antibody
SI2560653T1 (sl) Določeni aminopirimidini, sestavki le-teh in postopki za njihovo uporabo
BR112014012499A2 (pt) dispositivo de entrega e liberação para endoprótese
SI2729151T1 (sl) Farmacevtski sestavek, postopki za zdravljenje in njihove uporabe
ME03008B (me) Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti
HRP20170929T1 (hr) Farmaceutski pripravci i odgovarajući postupci za isporuku
HRP20190109T1 (hr) Ljudska antitijela na gfr 3 i načini za njihovu primjenu
ES2618221T8 (es) Dispositivo de administración de prótesis vascular y método de uso
HRP20180931T1 (hr) 11-hidroksil-6-supstituirani-derivati žučnih kiselina i njihovi aminokiselinski konjugati kao modulatori receptora za farnezoid x
DK2834348T3 (da) 3d in vitro bifasisk brusk-knogle-konstruktion
EP2680741A4 (en) RETINOGRAPH SYSTEM AND METHODOLOGY
EP2663548A1 (en) Pegylated lipids and their use for drug delivery
IL236920B (en) Ophthalmic compositions and their use for treatment of eye diseases and disorders in animals
HRP20181855T1 (hr) Lipidi za formulacije namijenjene unosu terapijskog sredstva
HRP20180126T1 (hr) Pripravci pcsk9 irna i postupci njihove upotrebe
HRP20190080T1 (hr) Postupak i formulacija za inhaliranje
BR112013025742A2 (pt) composição de vidros bioativos, sua utilização e respectivo métodos de obtenção.
HUE045348T2 (hu) Fehérje-hatóanyag konjugátumok és eljárás elõállításukra
SI2704703T1 (sl) Transdermalni sestavki ibuprofena in postopki za njihovo uporabo
EP2948896A4 (en) OPTIMIZED SYSTEM FOR DISPENSING A BIOSYNCHRONOUS BIOACTIVE MEDIUM
HRP20181882T1 (hr) Peptidi i konjugat peptid-aktivni sastojak za ciljanje bubrega lijekom
HRP20170928T1 (hr) Inhibitori kinurenin-3-monooksigenaze, farmaceutski pripravci, i postupci za njihovu upotrebu
BR112014010739A2 (pt) agentes terapêuticos e uso dos mesmos
BR112013023743A2 (pt) anticorpo de fator de tecidos humanos e usos do mesmo